Overview
- The University of Utah team published a peer‑reviewed Journal of Clinical Investigation paper on Sept. 1, 2026, reporting that EFHD1 drives hepatocyte injury in metabolic dysfunction‑associated steatohepatitis.
- Laboratory experiments showed EFHD1 increases contacts between the endoplasmic reticulum and mitochondria, which leads to mitochondrial fragmentation and leakage of double‑stranded RNA into the cytoplasm.
- That leaked RNA activates the kinase PKR and an antiviral‑like integrated stress response that worsens liver cell injury rather than protecting cells.
- Blocking or lowering EFHD1 cut measures of inflammation and fibrosis by about 30 to 60 percent in multiple mouse models and in human liver organoids, and the team has filed a provisional patent while developing EFHD1‑targeting approaches.
- EFHD1 variants in human genetic studies are linked to higher liver enzymes but not to more liver fat, which suggests targeting EFHD1 could reduce damage without directly lowering liver fat; human safety and efficacy still need clinical trials.